Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down - Should You Sell?

Key Points

• Tyra Biosciences shares fell sharply: The stock opened at $18.94 versus a prior close of $26.73 and was last trading near $20.47, down roughly 20%.
• Analysts remain broadly optimistic: Twelve analysts rate TYRA a Buy, one rates it Hold and one rates it Sell, producing a “Moderate Buy” consensus and an average price target of $48.22.
• Financial results remain pressured: Tyra reported quarterly EPS of -$0.69, missing the -$0.65 consensus estimate, while analysts expect a full-year loss of approximately $2.74 per share; institutional investors own 84.14% of the stock.

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $26.73, but opened at $18.94. Tyra Biosciences shares last traded at $20.4710, with a volume of 1,883,881 shares traded.

Analysts Set New Price Targets

A number of brokerages have commented on TYRA. Wolfe Research began coverage on shares of Tyra Biosciences in a research report on Tuesday, May 19th. They set a "peer perform" rating on the stock. HC Wainwright restated a "buy" rating and issued a $45.00 price objective on shares of Tyra Biosciences in a report on Friday, September 4th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $42.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, August 5th. Piper Sandler reaffirmed an "overweight" rating and set a $56.00 target price on shares of Tyra Biosciences in a report on Tuesday. Finally, JonesTrading initiated coverage on shares of Tyra Biosciences in a research report on Wednesday, June 17th. They issued a "buy" rating and a $56.00 target price on the stock. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $48.22.

Tyra Biosciences Trading Down 20.0%

The firm has a fifty day moving average of $28.85 and a two-hundred day moving average of $32.03. The company has a market capitalization of $1.28 billion, a PE ratio of -8.89 and a beta of 0.73.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.04). On average, equities analysts expect that Tyra Biosciences, Inc. will post -2.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

A number of large investors have recently modified their holdings of TYRA. Jupiter Topco LLC purchased a new position in Tyra Biosciences during the second quarter valued at $139,161,000. Janus Henderson Group PLC grew its position in shares of Tyra Biosciences by 32.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company's stock worth $148,867,000 after buying an additional 955,147 shares during the period. Commodore Capital LP grew its position in shares of Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company's stock worth $29,667,000 after buying an additional 2,150,000 shares during the period. BlackRock Inc. bought a new position in shares of Tyra Biosciences in the 2nd quarter worth about $96,841,000. Finally, Farallon Capital Management LLC increased its stake in shares of Tyra Biosciences by 80.7% in the 4th quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company's stock worth $54,337,000 after acquiring an additional 923,000 shares in the last quarter. Institutional investors own 84.14% of the company's stock.

Tyra Biosciences Company Profile

Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.